Gossamer Bio Inc

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 25, 2015 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.

Cerus

Cerus Inks FDA Contract, And Other News: The Good, Bad And Ugly Of Biopharma

Investors reacted forcefully Tuesday after Gossamer Bio Inc.'s (NASDAQ:GOSS) drug designated GB001 failed to achieve the hoped-for outcome in a study of patients with asthma and chronic sinus inflammation. Shares of the San Diego-based biotech fell more than 25% to $10.09.

Gossamer Shares Pummeled on Asthma Study Results

Gossamer Bio Inc. (NASDAQ: GOSS) shares dived on Tuesday after the company announced midstage results from its asthma and chronic rhinosinusitis studies.

Gossamer Bio Is Sucking Wind After This Asthma Study

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced topline results from its Phase 2b LEDA trial in patients with moderate-to-severe eosinophilic asthma and its Phase 2 TITAN trial in patients with chronic rhinosinusitis. “While we did not achieve statistical significance on the primary

Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), today announced multiple updates for its GB004 program. GB004 is an oral, gut-targeted HIF-1α stabilizer, designed to promote mucosal healing and resolve local inflammation through a non-immunosuppressive mechanism of action in patients with inflammatory bowel disease. Data Presented at UEGW Virtual 2020 William Sandborn, M.D., Chief of the Division of Gastroenterology of University of California San Diego, presented data at the UEG

Gossamer Bio Announces Presentation of GB004 Phase 1b Clinical Data at United European Gastroenterology Virtual Week 2020 and Additional Program Updates

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present data relevant to GB004 at United European Gastroenterology Virtual Week 2020, which takes place from October 11th through 13th. This includes an oral presentation from William Sandborn, M.D., Chief of the Division

Gossamer Bio Announces GB004 Data Presentations at United European Gastroenterology Virtual Week 2020

Investors need to pay close attention to Gossamer Bio (GOSS) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Gossamer Bio (GOSS) Stock?

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its participation in two upcoming investor conferences.

Gossamer Bio Announces Participation in Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present four posters with data relevant to its GB001 and GB002 programs at the Virtual European Respiratory Society International Congress 2020, which takes place from September 7th through 9th.

Gossamer Bio Announces Data Presentations at the Virtual European Respiratory Society International Congress 2020

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the second quarter 2020 and provided a corporate update.

Gossamer Bio Announces Second Quarter 2020 Financial Results and Provides Corporate Update

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present four posters with data relevant to its GB001 and GB002 programs at the American Thoracic Society 2020 Virtual Conference, which takes place from August 5th through 8th.

Gossamer Bio Announces Data Presentations at the American Thoracic Society 2020 Virtual Conference

As of late, it has definitely been a great time to be an investor in Gossamer Bio.

Gossamer Bio's Shares March Higher, Can It Continue?

Golar LNG

GW Pharmaceuticals

Lexinfintech Hlds

Nextcure

SINA

Millicom International Cellular S.A.

Casinos are just starting to open back up following COVID-19 shutdowns, but it may still be a while before some gamblers are willing to venture back to Vegas or even their local casino.

7 High-Risk Stocks For Market Gamblers

NEW YORK, May 20, 2020 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. ("Gossamer" or the "Company")(NASDAQ:GOSS) of the June 2, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that...

GOSSAMER DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Gossamer Bio, Inc. To Contact The Firm

Stock dilution is on the way for the small biotech.

Why Gossamer Bio Stock Is Tumbling Today

Gossamer Bio, Inc. (GOSS) CEO Sheila Gujrathi on Q1 2020 Results - Earnings Call Transcript

AcelRx Pharmaceuticals

Avinger

Genocea Biosciences

Village Farms International

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Bet on Rising P/E Investing  With These Top 5 Stocks

As of late, it has definitely been a great time to be an investor Gossamer Bio

Will Gossamer Bio Continue to Surge Higher?

Gossamer Bio (GOSS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Gossamer Bio (GOSS) Stock Might be a Great Pick

Gossamer Bio Inc (NASDAQ: GOSS) shares are tumbling to their lowest level since Oct.

Why Gossamer Bio Shares Are Plunging

Shares of biotech company Gossamer Bio tumbled in high volume Monday after rival pharmaceutical company Novartis scrapped an asthma treatment that failed to meet its goal in a Phase 3 study.
The post This Biotech Just Gave Up A Breakout — Why An Analyst Is Still Bullish appeared first on Investor's Business Daily.

This Biotech Just Gave Up A Breakout — Why An Analyst Is Still Bullish

Novartis is throwing in the towel on a drug similar to Gossamer's lead candidate.

Why Gossamer Bio Stock Is Crashing Today

Gossamer Bio, Inc. (GOSS) CEO Sheila Gujrathi on Q3 2019 Results - Earnings Call Transcript

Fresh off an initial public offering, the pharmaceutical company has taken investors on a wild ride.

News for Gossamer Bio Inc Stock (GOSS)